MYO

Myomo Appoints Heather Getz to its Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Robotics, Health, Technology, Neurology, Health Technology, General Health, Wearables, Mobile Technology, PICPA, Villanova University, AICPA, NACD, National Investor Relations Institute, Growth, Biotelemetry, Business administration, Strategic planning, NIRI, American Institute, Master of Business Administration, DSM-IV codes, Butterfly network, National Association, MYO, Certified Public Accountant, Management

Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership.

Key Points: 
  • Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership.
  • “We welcome Heather to the Myomo board of directors,” said Paul R. Gudonis, chairman and chief executive officer of Myomo.
  • "She brings financial and operational experience in scaling medical device and technology companies, which will be valuable to the board of directors as Myomo accelerates its growth."
  • “I am excited to join the Myomo board at such a pivotal time in the company’s history.

CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®

Retrieved on: 
Friday, March 1, 2024
Medical Supplies, Health, Medical Devices, Surgery, Other Health, General Health, Biotechnology, Weakness, Motion, CMS, Paralysis, Brace, MYO, Medicare, HCPCS, DSM-IV codes, Pharmaceutical industry

The final average fee schedule rates for the two Healthcare Common Procedures System (HCPCS) codes describing the MyoPro, L8701, our Motion W device, and L8702, our Motion G device, are $33,480.90 and $65,871.74, respectively, and can be found here beginning on page 67.

Key Points: 
  • The final average fee schedule rates for the two Healthcare Common Procedures System (HCPCS) codes describing the MyoPro, L8701, our Motion W device, and L8702, our Motion G device, are $33,480.90 and $65,871.74, respectively, and can be found here beginning on page 67.
  • On January 1, 2024, the MyoPro was officially classified in the brace benefit category, which enables reimbursement on a lump sum basis.
  • “This is an important milestone for qualified Medicare Part B beneficiaries with long-term muscular weakness or partial paralysis, and for Myomo as a company.
  • We extend thanks to the personnel at CMS for their efforts and for appreciating the benefits that powered braces such as the MyoPro can provide to Medicare Part B beneficiaries. "

Myomo to Report Fourth Quarter Financial Results on March 7, 2024

Retrieved on: 
Thursday, February 29, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Other Health, Health, Robotics, General Health, International, DSM-IV codes, Internet, MYO, PIN, Webcast

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.
  • The Company will host a conference call the same day, Thursday March 7, 2024 at 4:30 p.m.
  • ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
  • Those without internet access or unable to pre-register may dial in by calling, 1-844-707-6932 (U.S.) or 1-412-317-9250 (International).

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Retrieved on: 
Friday, January 19, 2024
Robotics, Health, Medical Devices, Technology, Other Technology, Other Health, Hardware, Patient, Madison Avenue, Research, Medicare (United States), Medicare, MYO, Prospectus, Public expenditure, Form, Sale, S-3, Telephone, Marketing, DSM-IV codes, Security (finance)

A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

Key Points: 
  • A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
  • The securities described above were offered pursuant to an effective shelf registration statement on Form S-3 (File No.
  • 333-256159) previously filed with the U.S. Securities and Exchange Commission (the “SEC”).
  • The offering is made only by means of a prospectus supplement and accompanying prospectus, which has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov .

Myomo Reports Preliminary Fourth Quarter Revenue and Backlog

Retrieved on: 
Wednesday, January 17, 2024
Neurology, Medical Supplies, General Health, Health, Medical Devices, Robotics, Health Technology, Technology, Medicare, Roger Hawkins (drummer), DSM-IV codes, Patient, MYO, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023.
  • Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago.
  • During the fourth quarter, the Company accelerated its efforts to identify and evaluate qualified Medicare Part B patients.
  • The Company plans to report financial results for the fourth quarter and year ended December 31, 2023 before March 15, 2024.

Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Retrieved on: 
Wednesday, January 17, 2024
General Health, Medical Devices, Health, Robotics, Technology, Patient, Madison Avenue, Research, Medicare (United States), Medicare, MYO, Prospectus, Public expenditure, Form, Sale, S-3, CMS, Telephone, Marketing, DSM-IV codes

The closing of the offering is expected to occur on or about January 19, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about January 19, 2024, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering to scale up operations to serve Medicare Part B patients now that CMS has established coverage and proposed pricing for the MyoPro product line.
  • A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting

Retrieved on: 
Monday, November 6, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Health Insurance, Health, Robotics, General Health, NYSE, HCPCS, Medicare, Motion, Weakness, Medicare Part D coverage gap, DSM-IV codes, MYO, Healthcare Common Procedure Coding System, Centers for Medicare & Medicaid Services, CMS, Pharmaceutical industry, Supply

CMS has proposed fee schedule rates for the two HCPCS codes describing the MyoPro, L8701, which is our Motion W device, and L8702, which is our Motion G device, of $31,745.42 and $62,457.28, respectively.

Key Points: 
  • CMS has proposed fee schedule rates for the two HCPCS codes describing the MyoPro, L8701, which is our Motion W device, and L8702, which is our Motion G device, of $31,745.42 and $62,457.28, respectively.
  • “We’re pleased to see the process moving forward to determine a national fee schedule rate from CMS for the MyoPro,” stated Paul R. Gudonis, Myomo’s Chairman and CEO.
  • “This is an important milestone for the Company and an important step in facilitating access to the MyoPro for qualified Medicare Part B beneficiaries with long-term muscular weakness or partial paralysis.”
    The preliminary payment determinations published by CMS for discussion at the public meeting are only proposed fee schedule rates.
  • The Company cannot provide any assurance that these rates will be finalized and published in their current amounts, or at all.

Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category

Retrieved on: 
Thursday, November 2, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Managed Care, Health, Robotics, General Health, Stroke, Insurance, Survivor, NYSE, Medicare, Paralysis, DME, Weakness, Medicare Part D coverage gap, Social, Social Security Act, Health equity, DSM-IV codes, MYO, Classification, Brace, Social Security, Centers for Medicare & Medicaid Services, Register, Patient, Federal Register, Health insurance, CMS

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rule classifying the MyoPro under the brace benefit category.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rule classifying the MyoPro under the brace benefit category.
  • Braces are paid on a lump sum basis under the Social Security Act.
  • This rule is expected to be published in the Federal Register on November 13, 2023 and is effective on January 1, 2024.
  • Future claims for devices delivered to patients are expected to continue to be reviewed on a claim-by-claim basis.

Myomo to Report Third Quarter Financial Results on November 7, 2023

Retrieved on: 
Tuesday, October 31, 2023
Neurology, General Health, Health, Medical Devices, Robotics, Wearables, Mobile Technology, Technology, Other Health, MYO, Internet, NYSE, Webcast, PIN, International, DSM-IV codes, Pharmaceutical industry

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023.
  • The Company will host a conference call the same day, Tuesday November 7, 2023 at 4:30 p.m.
  • ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
  • Those without internet access or unable to pre-register may dial in by calling, 1-844-707-6932 (U.S.) or 1-412-317-9250 (International).

Myomo Announces Closing of $4.4 Million Public Offering

Retrieved on: 
Tuesday, August 29, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Other Technology, Other Health, Health, Robotics, General Health, Centers for Medicare & Medicaid Services, Classification, Marketing, Telephone, DSM-IV codes, Managed file transfer, Research, Sale, Medicare, Public expenditure, Prospectus, S-3, Patient, MYO, Form, Madison Avenue, NYSE, Security (finance)

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses.
  • Members of management, affiliated investors and certain high-quality healthcare focused investors participated in the offering.
  • A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
  • The offering was made only by means of a prospectus supplement and accompanying base prospectus.